AgomAb Therapeutics NV (AGMB) Ownership
AGMB ownership summary
as of October 18, 2026- Institutions
- 53.7% of shares outstanding
- Insiders
- 5.97% of shares outstanding
- Shares outstanding
- 49.2M
- Float
- 11.4M shares available to trade
- Short interest
- 2.46% 1.0M shares short
- Days to cover
- 6.13 short interest up 15.4% vs prior month
- Institutions 53.72%
- Insiders 5.97%
- Other investors 40.32%
AGMB top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | EQT Fund Management S.à r.l. | 10.44% | 5.1M | $42.6M | — | June 30, 2026 |
| 2 | Nantahala Capital Management, LLC | 6.37% | 3.1M | $26.0M | +1.9M (+161.4%) | June 30, 2026 |
| 3 | Sanofi | 5.65% | 2.8M | $23.0M | — | June 30, 2026 |
| 4 | Redmile Group, LLC | 5.55% | 2.7M | $22.6M | +2.6M (+1,649.7%) | June 30, 2026 |
| 5 | Cormorant Asset Management, LLC | 5.01% | 2.5M | $20.4M | — | June 30, 2026 |
| 6 | TCG Crossover Management, LLC | 4.17% | 2.1M | $17.0M | — | June 30, 2026 |
| 7 | Federated Hermes Inc | 3.29% | 1.6M | $13.4M | — | June 30, 2026 |
| 8 | Casdin Capital, LLC | 3.15% | 1.6M | $12.8M | — | June 30, 2026 |
| 9 | Andera Partners | 3.12% | 1.5M | $12.7M | — | June 30, 2026 |
| 10 | FMR Inc | 2.96% | 1.5M | $12.1M | — | June 30, 2026 |
| 11 | Aberdeen Group PLC | 1.72% | 847K | $7.0M | +139,039 (+19.6%) | June 30, 2026 |
| 12 | Perceptive Advisors LLC | 1.22% | 600K | $5.0M | — | June 30, 2026 |
| 13 | Samsara BioCapital, LLC | 1.22% | 600K | $5.0M | — | June 30, 2026 |
| 14 | Siren, L.L.C. | 0.84% | 411K | $3.4M | — | June 30, 2026 |
| 15 | Orbimed Advisors LLC | 0.39% | 193K | $1.6M | +192,740 (0.0%) | June 30, 2026 |
| 16 | Pfizer Inc | 0.15% | 75K | $621,000 | — | June 30, 2026 |
| 17 | ALPS Advisors Inc | 0.10% | 50K | $413,868 | +49,984 (0.0%) | June 30, 2026 |
| 18 | Bellevue Group AG | 0.10% | 49K | $407,773 | −752 (−1.5%) | June 30, 2026 |
| 19 | SEVEN GRAND MANAGERS, LLC | 0.10% | 48K | $394,128 | −152,400 (−76.2%) | June 30, 2026 |
| 20 | Sectoral Asset Management Inc | 0.09% | 44K | $360,180 | — | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 5 holders added 4.9M shares and 2 cut 153K.
AGMB top mutual fund and ETF holders
17 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Federated Hermes Kaufmann R | 1.99% | 981K | $8.1M | — | June 30, 2026 |
| 2 | Federated Hermes Kaufmann Small Cap A | 1.25% | 616K | $5.1M | — | June 30, 2026 |
| 3 | Fidelity Growth Company Fund | 1.03% | 507K | $4.2M | — | August 31, 2026 |
| 4 | abrdn Healthcare Investors | 0.94% | 463K | $3.8M | +99,775 (+27.4%) | August 31, 2026 |
| 5 | abrdn World Healthcare | 0.84% | 414K | $3.4M | +101,727 (+32.5%) | August 31, 2026 |
| 6 | abrdn Life Sciences Investors | 0.67% | 330K | $2.7M | +75,913 (+29.9%) | August 31, 2026 |
| 7 | Fidelity Growth Company K6 | 0.29% | 142K | $1.2M | — | August 31, 2026 |
| 8 | Fidelity Series Growth Company | 0.26% | 129K | $1.1M | — | August 31, 2026 |
| 9 | Biotech Growth Ord | 0.23% | 112K | $923,551 | +14,434 (+14.9%) | June 30, 2026 |
| 10 | ALPS Medical Breakthroughs ETF | 0.13% | 65K | $536,362 | — | September 30, 2026 |
| 11 | Protea Sectoral Hlthcare Opps P USD Acc | 0.05% | 27K | $223,022 | — | June 30, 2026 |
| 12 | Steward Values Enhanced International I | 0.05% | 23K | $191,235 | +18,987 (+462.1%) | August 31, 2026 |
| 13 | Federated Hermes Kaufmann II P | 0.04% | 21K | $174,774 | — | June 30, 2026 |
| 14 | Protea Sectoral Biotech Opps IF USD Acc | 0.03% | 17K | $137,158 | — | June 30, 2026 |
| 15 | Fidelity Nasdaq Composite Index | 0.02% | 9,531 | $78,917 | — | August 31, 2026 |
| 16 | Fidelity Select Pharmaceuticals Port | 0.02% | 9,100 | $75,348 | — | August 31, 2026 |
| 17 | Bellevue Diversified Healthcare U2 CHF | <0.01% | 1,881 | $15,575 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
Who owns AGMB
Institutional investors own 53.7% of AgomAb Therapeutics NV's shares and insiders 5.97%. The largest holder is EQT Fund Management S.à r.l. with 10.44% of the shares (5.1M), as of June 30, 2026. Among the top 20 institutions, 5 added shares and 2 reduced their stake in the latest filings. Short interest is 2.46% of the float, or 6.13 days of average trading volume. The share count rose 34.5% since 2024.
Related: AGMB analyst forecast, AGMB key metrics. See the AGMB stock overview for the latest quote and news.
AGMB ownership FAQ
Who owns the most AgomAb Therapeutics NV stock?
The largest shareholders of AgomAb Therapeutics NV are EQT Fund Management S.à r.l. (10.44%), Nantahala Capital Management, LLC (6.37%), Sanofi (5.65%), Redmile Group, LLC (5.55%), Cormorant Asset Management, LLC (5.01%).
What percentage of AgomAb Therapeutics NV is owned by institutions?
Institutions hold 53.7% of AgomAb Therapeutics NV's shares outstanding; insiders hold 5.97%.
Which funds own AgomAb Therapeutics NV?
The largest fund holders of AgomAb Therapeutics NV are Federated Hermes Kaufmann R (1.99%), Federated Hermes Kaufmann Small Cap A (1.25%), Fidelity Growth Company Fund (1.03%), abrdn Healthcare Investors (0.94%), abrdn World Healthcare (0.84%).
What is AgomAb Therapeutics NV's short interest?
1.0M shares of AgomAb Therapeutics NV were sold short, 2.46% of the float; at the average daily volume it would take 6.13 days to cover.
How many shares of AgomAb Therapeutics NV are outstanding?
AgomAb Therapeutics NV has 49.2M shares outstanding, of which 11.4M are in the public float.